Julia Driessen1, Seo Hyon Baik1, Yuting Zhang1. 1. Dr. Driessen and Dr. Zhang are with the Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, Pennsylvania (e-mail: driessen@pitt.edu ). Dr. Baik is with the Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland.
Abstract
OBJECTIVE: The study evaluated trends in the off-label use of second-generation antipsychotics in the Medicare population, a practice that has been identified as lacking adequate supporting evidence for many indications. METHODS: Medicare claims data from 2006 to 2012 were used to identify beneficiaries who filled at least one prescription for any second-generation antipsychotic. Any use that was not associated with a medical claim for an approved indication in a given year was classified as off-label use. Rates of off-label use and of diagnoses associated with off-label use were compared over time. Fill counts standardized for 30-day supply and costs were compared by type of use. RESULTS: On the basis of a sample of 490,314 patient-years, the rate of off-label use among beneficiaries prescribed a second-generation antipsychotic declined from 51% to 45%. Fill counts were 16% lower for off-label users compared with on-label users. Off-label users had higher out-of-pocket costs but lower total costs for second-generation antipsychotics. Off-label users most commonly had claims related to dementia, minor depression, anxiety disorders, and other psychosis. The proportion of off-label users without any claims for the most common off-label uses of second-generation antipsychotics declined from 45% in 2006 to 30% in 2012. CONCLUSIONS: Off-label use of second-generation antipsychotics has declined, especially among persons without any of the common off-label conditions. The diagnoses accompanying off-label use did not systematically reflect changes in the evidence base for the use of these drugs, suggesting a mismatch between evidence supporting the use of off-label second-generation antipsychotics and prescribing practices.
OBJECTIVE: The study evaluated trends in the off-label use of second-generation antipsychotics in the Medicare population, a practice that has been identified as lacking adequate supporting evidence for many indications. METHODS: Medicare claims data from 2006 to 2012 were used to identify beneficiaries who filled at least one prescription for any second-generation antipsychotic. Any use that was not associated with a medical claim for an approved indication in a given year was classified as off-label use. Rates of off-label use and of diagnoses associated with off-label use were compared over time. Fill counts standardized for 30-day supply and costs were compared by type of use. RESULTS: On the basis of a sample of 490,314 patient-years, the rate of off-label use among beneficiaries prescribed a second-generation antipsychotic declined from 51% to 45%. Fill counts were 16% lower for off-label users compared with on-label users. Off-label users had higher out-of-pocket costs but lower total costs for second-generation antipsychotics. Off-label users most commonly had claims related to dementia, minor depression, anxiety disorders, and other psychosis. The proportion of off-label users without any claims for the most common off-label uses of second-generation antipsychotics declined from 45% in 2006 to 30% in 2012. CONCLUSIONS: Off-label use of second-generation antipsychotics has declined, especially among persons without any of the common off-label conditions. The diagnoses accompanying off-label use did not systematically reflect changes in the evidence base for the use of these drugs, suggesting a mismatch between evidence supporting the use of off-label second-generation antipsychotics and prescribing practices.
Authors: Hua Chen; Jaxk H Reeves; Jack E Fincham; William K Kennedy; Jeffrey H Dorfman; Bradley C Martin Journal: J Clin Psychiatry Date: 2006-06 Impact factor: 4.384
Authors: Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis Journal: Arch Gen Psychiatry Date: 2006-10
Authors: Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao Journal: N Engl J Med Date: 2005-09-19 Impact factor: 91.245
Authors: Stephen Crystal; Mark Olfson; Cecilia Huang; Harold Pincus; Tobias Gerhard Journal: Health Aff (Millwood) Date: 2009-07-21 Impact factor: 6.301
Authors: Jennifer A Watt; Tara Gomes; Susan E Bronskill; Anjie Huang; Peter C Austin; Joanne M Ho; Sharon E Straus Journal: CMAJ Date: 2018-11-26 Impact factor: 8.262
Authors: Adam Sacarny; Michael L Barnett; Jackson Le; Frank Tetkoski; David Yokum; Shantanu Agrawal Journal: JAMA Psychiatry Date: 2018-10-01 Impact factor: 21.596
Authors: Stefanie N Rezansoff; A Moniruzzaman; S Fazel; R Procyshyn; J M Somers Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2016-06-23 Impact factor: 4.328